Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000125.xml
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2023; 20(02): 159-169
DOI: 10.1055/a-2079-8481
DOI: 10.1055/a-2079-8481
Übersicht
Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien
Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
Zusammenfassung
Die in den letzten Jahren begonnenen großen Studienprogramme zu den CDK4/6-Inhibitoren, den zielgerichteten Therapien und den Antikörper-Medikament-Konjugaten resultieren in Ergebnissen, die von aktuellen Studien auf internationalen Kongressen und Fachzeitschriften veröffentlicht werden. In diesem Zusammenhang sind neue Ergebnisse der großen CDK4/6-Inhibitor-Studien verfügbar. Auch werden zunehmend Daten von großen genomischen Studien zu Effektivitäts- und Resistenzmechanismen für Patientinnen, die mit CDK4/6-Inhibitoren behandelt worden sind, veröffentlicht. Basierend auf diesen Ergebnissen sollten nicht zuletzt Studien in Bezug auf Kombinationspartner und Therapiesequenzen geplant werden. Mit Sacituzumab Govitecan ist aufgrund neuester Veröffentlichungen nun ein zweites Antikörper-Medikament-Konjugat vorhanden, das bei hormonrezeptorpositiven (HRpos)/HER2-negativen (HER2neg) Patientinnen einen Gesamtüberlebensvorteil mit sich bringt. Diese Übersichtsarbeit fasst die neuesten Entwicklungen zusammen und ordnet sie in den aktuellen Forschungsstand ein.
Abstract
Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptorpositive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.
Publication History
Received: 27 November 2022
Accepted after revision: 23 January 2023
Article published online:
16 June 2023
© 2022. This article was originally published by Thieme as Diana Lüftner et al., Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer. Geburtshilfe Frauenheilkd 2023; 83: 299–309 as an open access article under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Slamon DJ, Neven P, Chia S. et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol 2021; 32: 1015-1024 DOI: 10.1016/j.annonc.2021.05.353.
- 2 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646 DOI: 10.1200/JCO.2017.75.6155.
- 3 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472 DOI: 10.1200/JCO.2018.78.9909.
- 4 Sledge Jr GW, Toi M, Neven P. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35: 2875-2884 DOI: 10.1200/JCO.2017.73.7585.
- 5 Turner NC, OʼLeary B, Cutts R. et al. Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. J Clin Oncol 2018; 36: 1001
- 6 Sledge Jr GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2019; DOI: 10.1001/jamaoncol.2019.4782.
- 7 Cristofanilli M, Turner NC, Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptorpositive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425-439 DOI: 10.1016/S1470-2045(15)00613-0.
- 8 Tripathy D, Im SA, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018; DOI: 10.1016/S1470-2045(18)30292-4.
- 9 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936 DOI: 10.1056/NEJMoa1607303.
- 10 Hortobagyi GN, Stemmer SM, Burris HA. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950 DOI: 10.1056/NEJMoa2114663.
- 11 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748 DOI: 10.1056/NEJMoa1609709.
- 12 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316 DOI: 10.1056/NEJMoa1903765.
- 13 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524 DOI: 10.1056/NEJMoa1911149.
- 14 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219 DOI: 10.1056/NEJMoa1505270.
- 15 Turner NC, Slamon DJ, Ro J. et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936 DOI: 10.1056/NEJMoa1810527.
- 16 Luftner D, Schutz F, Stickeler E. et al. Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 215-225 DOI: 10.1055/a-1724-9569.
- 17 Goetz MP, Toi M, Huober J. et al. MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol 2022; 33 (Suppl. 07) S808-S869 DOI: 10.1016/annonc/annonc1089.
- 18 European Medicines Agency. Verzenios. 2022 Online (Stand: 20.11.2022): https://www.emaeuropa.eu/en/medicines/human/summaries-opinion/verzenios
- 19 Allison KH, Hammond MEH, Dowsett M. et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 2020; 38: 1346-1366 DOI: 10.1200/JCO.19.02309.
- 20 Wang J, Li Q, Yuan J. et al. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Transl Med 2017; 15: 127 DOI: 10.1186/s12967-017-1231-7.
- 21 Long F, He Y, Fu H. et al. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sci 2019; 110: 1420-1430 DOI: 10.1111/cas.13957.
- 22 Xu B, Zhang Q, Zhang P. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med 2021; 27: 1904-1909 DOI: 10.1038/s41591-021-01562-9.
- 23 Xu B, Zhang QY, Zhang P. et al. Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial. Ann Oncol 2022; 33 (Suppl. 07) S808-S869 DOI: 10.1016/annonc/annonc1089.
- 24 Bidard FC, Hardy-Bessard AC, Dalenc F. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2022; 23: 1367-1377 DOI: 10.1016/S1470-2045(22)00555-1.
- 25 Laine M, Fanning SW, Chang YF. et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res 2021; 23: 54 DOI: 10.1186/s13058-021-01431-w.
- 26 Andreano KJ, Baker JG, Park S. et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther 2020; 19: 1395-1405 DOI: 10.1158/1535-7163.MCT-19-1148.
- 27 Goetz MP, Plourde P, Stover DG. et al. Open-label, randomized study of lasofoxifene (LAS) vs. fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors. Ann Oncol 2022; 33 (Suppl. 07) S808-S869 DOI: 10.1016/annonc/annonc1089.
- 28 Safonov A, Bandlamudi C, Tallón de Lara P. et al. Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactionsmediating therapy resistanc. San Antonio Breast Cancer Symposium 2021; 2021: GS4-08
- 29 Marra A, Gazzo A, Gupta A. et al. Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) ± CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC). Ann Oncol 2022; 33 (Suppl. 07) S88-S121 DOI: 10.1016/annonc/annonc1089.
- 30 Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014; 24: 52-60 DOI: 10.1016/j.gde.2013.11.014.
- 31 Alexandrov LB, Kim J, Haradhvala NJ. et al. The repertoire of mutational signatures in human cancer. Nature 2020; 578: 94-101 DOI: 10.1038/s41586-020-1943-3.
- 32 COSMIC. Mutational Signatures (v3.3 – June 2022)- Single Base Substitution (SBS) Signatures. 2022 Online (Stand: 12.11.2022): https://cancer.sanger.ac.uk/signatures/sbs/
- 33 clinicaltrials.gov. Comprehensive Analysis of Spatial, Temporal and Molecular Patters of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC). 2022 Online (Stand: 16.07.2022): https://clinicaltrials.gov/ct2/show/NCT05452213
- 34 clinicaltrials.gov. Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA). 2022 Online (Stand: 26.06.2022): https://clinicaltrials.gov/ct2/show/NCT05362760
- 35 Bidard FC, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-3256 DOI: 10.1200/JCO.22.00338.
- 36 AstraZeneca. Camizestrant significantly improved progression-free survival vs. Faslodex in SERENA-2 Phase II trial in advanced ER-positive breast cancer. 2022 Online (Stand: 20.11.2022): https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrantsignificantly-improved-progression-free-survival.html
- 37 Tolaney SM, Chan A, Petrakova K. et al. AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physicianʼs choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC). Ann Oncol 2022; 33 (Suppl. 07) S80-S121 DOI: 10.1016/annonc/annonc1089.
- 38 Jimenez MM, Lim E, Gregor MCM. et al. Giredestrant (GDC-9545) vs. physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol 2022; 33 (Suppl. 07) S808-S869 DOI: 10.1016/annonc/annonc1089.
- 39 Sanofi. Sanofi provides update on amcenestrant clinical development program. 2022 Online (Stand: 03.11.2022): https://www.sanofi.com/en/media-room/press-releases/2022/2022-08-17-05-30-00-2499668
- 40 Di Cosimo S, Perez-Garcia JM, Bellet M. et al. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. Oncologist 2023; 28: 23-32 DOI: 10.1093/oncolo/oyac205.
- 41 Ruiz-Borrego M, Guerrero-Zotano A, Bermejo B. et al. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. Breast Cancer Res Treat 2019; 177: 115-125 DOI: 10.1007/s10549-019-05296-8.
- 42 Rugo HS, Bardia A, Marmé F. et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physicianʼs choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol 2022; 40: LBA1001-LBA1001 DOI: 10.1200/JCO.2022.40.17_suppl.LBA1001.
- 43 Rugo HS, Bardia A, Marmé F. et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs. treatment of physicianʼs choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Ann Oncol 2022; 33 (Suppl. 07) S808-S869 DOI: 10.1016/annonc/annonc1089.
- 44 Engler T, Fasching PA, Luftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022; 82: 1055-1067 DOI: 10.1055/a-1880-0087.
- 45 Hartkopf A. Therapy landscapes and molecular markers, the German PRAEGNANT registry. ESMO Breast Cancer Conference 2022. 2022 Online (Stand: 10.11.2022): https://oncologypro.esmo.org/meetingresources/esmo-breast-cancer-congress/therapy-landscapes-andmolecular-markers-the-german-praegnant-registry
- 46 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20 DOI: 10.1056/NEJMoa2203690.
- 47 Rugo HS, Bardia A, Marme F. et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2022; 40: 3365-3376 DOI: 10.1200/JCO.22.01002.
- 48 Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 2015; 3: 436-443 DOI: 10.1158/2326-6066.CIR-15-0064.
- 49 Opzoomer JW, Sosnowska D, Anstee JE. et al. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. Front Immunol 2019; 10: 1654 DOI: 10.3389/fimmu.2019.01654.
- 50 Munzone E, Regan MM, Cinieri S. et al. A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs. weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16). Ann Oncol 2022; 33 (Suppl. 07) S88-S121 DOI: 10.1016/annonc/annonc1089.
- 51 clinicaltrials.gov. NCT05033769. Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE). NIH US National Library of Medicine 2022. Online (Stand: 01.11.2022): https://clinicaltrials.gov/ct2/show/NCT05033769
- 52 Janni W, Schneeweiss A, Muller V. et al. Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Frauenheilkd 2019; 79: 268-280 DOI: 10.1055/a-0842-6661.
- 53 OʼBrien NA, McDonald K, Tong L. et al. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 2014; 20: 3507-3520 DOI: 10.1158/1078-0432.CCR-13-2769.
- 54 Loibl S, von Minckwitz G, Schneeweiss A. et al. PIK3CA mutations are associated with lower rates of pathologic complete response to antihuman epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32: 3212-3220 DOI: 10.1200/JCO.2014.55.7876.
- 55 Schlam I, Tarantino P, Tolaney SM. Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. Cancers (Basel) 2022; 14: 3996 DOI: 10.3390/cancers14163996.
- 56 Xu B, Yan M, Ma F. et al. Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial. Ann Oncol 2022; 33 (Suppl. 07) S808-S869 DOI: 10.1016/annonc/annonc1089.
- 57 Swain SM, Baselga J, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734 DOI: 10.1056/NEJMoa1413513.
- 58 Baselga J, Cortes J, Kim SB. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119 DOI: 10.1056/NEJMoa1113216.
- 59 Muller V, Welslau M, Luftner D. et al. Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 590-600 DOI: 10.1055/a-1811-6148.
- 60 Aktas B, Fehm TN, Welslau M. et al. Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 922-931 DOI: 10.1055/a-1912-7362.
- 61 Ditsch N, Stickeler E, Behrens A. et al. Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers. Geburtshilfe Frauenheilkd 2021; 81: 539-548 DOI: 10.1055/a-1464-1221.
- 62 Tesch H, Muller V, Wockel A. et al. Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80: 1115-1122 DOI: 10.1055/a-1270-7481.
- 63 André F, Nadal JC, Denys H. et al. Final overall survival (OS) for abemaciclib plus trastuzumab ± fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial. Ann Oncol 2022; 33 (Suppl. 07) S808-S869 DOI: 10.1016/annonc/annonc1089.